AZA-TDC capsules for use in clinical trial for possible cancer treatment. The drug product (DP) will be a 4 MG strength capsule which is not available in the market, and no other alternative exist…
Ended Awarded Last action
- Contract number
- 75N91022F00001
- Awardee
-
Societal Cdmo San Diego, LLC UEI YRPTVKHDL7Z5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $153,336
Award facts
- Contract value 100% obligated
- $153,336.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6850 Miscellaneous Chemical Specialties
- Set-aside
- No set-aside
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Terminate for Convenience | -$23,799 | |
| Original award | $177,135 |
About this award
This is a firm fixed-price delivery order issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Societal CDMO San Diego, LLC (a division of Recro Pharma, Inc.) for the production of 5,000 capsules of a 4 mg strength investigational cancer drug product, AZA-TDC, that is not commercially available. The contract has a total potential value of $153,336.00 and a completion date of March 31, 2024. It was awarded on November 19, 2021 under the parent Drug Formulation and Manufacturing Contracts 2019 indefinite delivery, indefinite quantity (IDIQ) contract vehicle. Societal CDMO San Diego is a small disadvantaged business that provides drug development and manufacturing services to federal agencies, including HHS and the Department of Veterans Affairs (VA), in support of their clinical research initiatives.
Description
AZA-TDC capsules for use in clinical trial for possible cancer treatment. The drug product (DP) will be a 4 MG strength capsule which is not available in the market, and no other alternative exist except the use of the contract process.
Quick answers
Who was awarded contract 75N91022F00001?
75N91022F00001 was awarded to Societal Cdmo San Diego, LLC by National Cancer Institute (National Institutes of Health) on November 19, 2021.
How much is contract 75N91022F00001 worth?
The government has obligated $153,336 on 75N91022F00001.
Is contract 75N91022F00001 an order under another contract?
Yes. 75N91022F00001 is a delivery order under 75N98019D00058, an indefinite delivery contract, on Drug Formulation and Manufacturing Contracts 2019.
Was contract 75N91022F00001 competed?
The extent of competition for 75N91022F00001 was full and open competition after exclusion of sources. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award